On December 2, 2022 Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, reported that the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 – 10, 2022 in San Antonio, Texas (Press release, BioThera Solutions, DEC 2, 2022, View Source [SID1234624715]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first poster, entitled "BAT8006, a novel FRα-ADC with strong bystander effect, for the treatment of advanced solid tumor," will present preclinical data and initial phase 1 clinical data that highlight advantages demonstrated by BAT8006 as a potential treatment for patients with solid tumors, such as ovarian cancer and breast cancer. An abstract of the presentation is currently available on the SABCS website.
Presentation details are as follows:
Poster Session:
Session Date and Time:
Thursday, December 8, 7:00 am – 8:15 am
Location:
Poster Area/Exhibition Hall
Poster Board Number:
P4-01-12
The second poster, entitled "BAT8008, a novel Trop-2 ADC with strong bystander effect, for the treatment of Trop-2 positive cancer," will present preclinical data that highlight advantages demonstrated by BAT8008 as a potential treatment for Trop-2 positive cancer patients. An abstract of the presentation is currently available on the SABCS website.
Presentation details are as follows:
Poster Session:
Session Date and Time:
Thursday, December 8, 7:00 am – 8:15 am
Location:
Poster Area/Exhibition Hall
Poster Board Number:
P4-01-32
BAT8006 and BAT8008 are two new ADC assets being developed with Bio-Thera’s next-gen ADC platform that utilizes a systemically stable cleavable linker, a potent Topoisomerase 1 inhibitor (Exatecan) as the payload, and high DARs that takes advantage of the bystander effect to increase efficacy. Other new ADC assets developed using this next-gen ADC platform include BAT8007 (Nectin4-ADC), BAT8009 (B7-H3-ADC) and BAT8010 (Her2-ADC). All of these ADC assets are currently in, or about to begin, Phase 1 clinical trials.
About BAT8006
BAT8006 is an investigational Folate Receptor-alpha-ADC being evaluated in multiple tumor types. Folate Receptor is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and ovarian cancer. BAT8006 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. BAT8006 is currently being evaluated in a Phase 1 clinical trial evaluating the pharmacodynamics and safety of BAT8006 (more information on the Phase 1 clinical trial is available at View Source).
About BAT8008
BAT8008 is an investigational Trop-2-ADC being evaluated in multiple tumor types. Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer. BAT8008 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. BAT8008 is currently being evaluated in a Phase 1 clinical trial evaluating the pharmacodynamics and safety of BAT8008 (more information on the Phase 1 clinical trial is available at View Source).